January 1, 2022 OHIO LIONS EYE RESEARCH FOUNDATION (OLERF)
This year marks 70 years since formation of the initial Ohio Lions Eye Research Committee and 65 years since obtaining 501(c)(3) tax-exempt status. The Ohio Lions Eye Research Foundation (OLERF) has been committed to finding treatments and cures for blinding retinal diseases. With your support, we have been able to develop new breakthroughs and fund groundbreaking research that provides hope to those living with blinding retinal diseases through our grants and fellowships. However, there is still much more work to be done in the fight against blindness, and we cannot do it without you. Now is the time to renew/continue your dedication to ending blindness and vision loss here and around the world.
You can help OLERF find treatments and cures by continuing your commitment as a supporter to those affected by retinal diseases. Just look at what we have been able to accomplish together however, there is still more work to be done and we will not stop until we have eradicated blinding retinal diseases and restored vision across the world.
- All funds received by OLERF remain in Ohio for research
- $579,291.47 committed last year for 11 research projects
- Over $7 million dollars have been given to Ohio researchers by OLERF
More than 10 million Americans - and millions more worldwide - live with blinding retinal diseases. Your support brings hope for therapies, treatments, and cures. Each District in Ohio has an OLERF member. Contact them for more information or to donate.
February 16, 2022 OHIO LIONS EYE RESEARCH FOUNDATION (OLERF) Zoom Meeting
We're serious about efforts for Eye Research Today ... Vision Tomorrow. Today's discussion focused on many topics including Awards and the Foundation's Code of Regulations.
April 13, 2022 Lois Hagelberger-Huebner Young Investigator In The News
"Ohio State’s Early Career Innovator of the year for 2022 is Katelyn Swindle-Reilly, Phd, an assistant professor in the College of Engineering. Dr. Swindle-Reilly's current research interests focus on the design of polymeric biomaterials for soft tissue repair and drug delivery with focused applications in ophthalmology and wound healing. Dr. Swindle-Reilly received recognition for her work on treatments for patients with conditions such as age-related macular degeneration and other retinal diseases. These patients may need injections straight into the eye up to 12 times per year. She has developed an extended release capsule that – while still injected into the eye – can reduce the timing of injections to once or twice a year." Reference
Dr. Katelyn Swindle-Reilly had received the Lois Hagelberger-Huebner Young Investigator Award from the Ohio Lions Eye Research Foundation. The proposal was titled “Sustained Release Bevacizumab Injectable for the Treatment of Wet Age-Related Macular Degeneration." The award was for $107,000 per year for two years, September 15, 2017 to September 14, 2019.